🟢 100/100

This product looks safe

  • No ingredients exceed tolerable upper intake levels
  • 14% of ingredients have research evidence
B Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Label Data

4 Capsule(s) Serving Size
30 Servings
Other Combinations Product Type
14% Evidence Coverage

Supplement Facts — Evidence Check

30 mg NE (188% DV)
✅ 2.1× RDA — within safe limits 📚 193 studies (Tier A: 5, B: 63)
RDA 14mg This product: 30mg UL 35mg
1.1 Gram(s)
📊 Market median: 500.0mg (143 products)
This product: 1.1mg
📊 Market median: 500.0mg (143 products)
This product: 1.1mg
📊 Market median: 2000.0mg (275 products)
Median 2000.0mg This product: 500mg
Agmatine Sulfate
100 mg
Masson Pine bark extract
100 mg
Bioperine
5 mg

Other Ingredients

Hypromellose Rice Flour Magnesium Stearate

Label Claims — Verification

All Other
Structure/Function
All Other (97% of products) Structure/Function (86% of products) Nutrient (36% of products)

Target Groups

Adult (18 - 50 Years) Women (not pregnant or lactating)

Product Information

📋 Directions for Use

Directions As a dietary supplement take 4 capsules 30 minutes prior to working out. On non-workout days, take four (4) capsules in the morning or night.

⚠️ Warnings & Precautions

Warning: Do not exceed recommended daily dosage.

This product should only be taken by healthy individuals at least 18 years of age or older. Keep out of reach of children.

Do not consume if pregnant or nursing.

You should not take this product with alcohol. Discontinue use and consult a medical doctor if you experience unusual symptoms. Do not use if safety seal is damaged or missing.

Manufactured in a facility with fish, wheat, gluten, milk, egg, shellfish, tree nuts, soy, peanut.

🧪 Formulation Notes

Muscle growth Endurance Fuller pumps

Additional Information

GMP Compliant Good Manufacturing Practice

Store in a cool, dry place.

Made in the USA

Product Details

UPC / SKU X002K0WQHJ
DSLD Entry Date 2022-05-19
Product Type Other Combinations
Form Capsule
DSLD ID 263523
Data Updated 2026-04-11

Research Evidence

241 Research Sources
55 Avg Quality Score
113 Meta Analysis
75 Systematic Review
32 Rct
11 Clinical Trial
3 Other
3 Regulatory Source
1 Cochrane Review
1 Narrative Review
1 Openfda Safety
A Niacin for primary and secondary prevention of cardiovascular events
Meta Analysis The Cochrane database of systematic reviews 2017
A Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases
Meta Analysis BMJ (Clinical research ed.) 2013
A Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients
Meta Analysis BMJ (Clinical research ed.) 2014
A A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk
Meta Analysis Nature medicine 2024
A Meta-analysis and imputation refines the association of 15q25 with smoking quantity
Meta Analysis Nature genetics 2010
A Genome-wide meta-analyses identify multiple loci associated with smoking behavior
Meta Analysis Nature genetics 2010
A Antidepressants for smoking cessation
Meta Analysis The Cochrane database of systematic reviews 2014
A Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne
Meta Analysis The Cochrane database of systematic reviews 2020
B Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis
Meta Analysis JAMA network open 2019
B Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis
Meta Analysis JAMA 2016
View all evidence for Niacin →

Compare Similar Products

View all Niacin products →